Accessibility Menu

Novo Nordisk A/s(FRA) NOVC

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2001)+3,457%
5 Year-12%
1 Year-16%
1 Month-5%
N/A
Novo Nordisk A/s last closing stock price
MetricPriceDate
Last closeEUR 39.992026-08-21
Novo Nordisk A/s stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.52%EUR 39.392026-08-14
1 month-5.37%EUR 42.262026-07-22
3 month+3.41%EUR 38.672026-05-22
Year to date-9.15%EUR 44.022025-12-30
1 year-16.18%EUR 47.712025-08-21
3 year-53.07%EUR 85.222023-08-22
5 year-12.11%EUR 45.502021-08-20
Since inception+3,457.37%EUR 1.132001-11-19

Novo Nordisk A/s Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$44.11K

Net Income (TTM)

$15.59K

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

NOVC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Novo Nordisk A/s

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Industry

Pharmaceuticals

Sector

Health Care

Employees

68,794

CEO

Maziar Mike Doustdar

Website

www.novonordisk.com

NOVC Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

N/A

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Payout Ratio

N/A

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Novo Nordisk A/s Performance Analysis

Novo Nordisk A/s annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 23,785,986,66225.6%
20232023-12-31USD 31,171,779,60031.1%
20242024-12-31USD 38,934,419,21124.9%
20252025-12-31USD 41,411,215,7736.4%
Novo Nordisk A/s annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 1.6417.8%
20232023-12-31USD 2.5052.1%
20242024-12-31USD 3.0321.4%
20252025-12-31USD 3.091.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$10.50K

+1.0%

Gross Profit

$8.21K

+1.0%

Gross Margin

78.21%

+0.9%

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.71

+0.8%

Employees

68,794

+0.9%

Net Income

$2.81K

+0.8%

EBITDA

$5.03K

+1.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$24.70K

+56.5%

Total Debt

$18.75K

+1.4%

Accounts Receivable

$11.90K

+1.3%

Inventory

$6.87K

+1.1%

Long Term Debt

$16.29K

+1.4%

Short Term Debt

$2.45K

+1.5%

Return on Assets

21.62%

+0.8%

Return on Invested Capital

50.10%

+0.9%

Free Cash Flow

$5.46K

+6.9%

Operating Cash Flow

$7.15K

+2.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,674.37+0.00%
^DJIDJI
$53,277.01+0.01%
^IXICNASDAQ
$26,180.45+0.00%
BTCBitcoin
$77,351.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.77+0.10%
IBITiShares Bitcoin Trust
$43.68+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$10.41+0.06%
MARAMara Holdings
$11.26+0.01%

Questions About NOVC

What is the current price of Novo Nordisk A/s?

Novo Nordisk A/s is trading at N/A per share.

What is the 52-week range for Novo Nordisk A/s?

Over the past 52 weeks, Novo Nordisk A/s has traded between N/A and N/A.

How much debt does Novo Nordisk A/s have?

As of the most recent reporting period, Novo Nordisk A/s reported total debt of $18.75B.

How much cash does Novo Nordisk A/s have on hand?

Novo Nordisk A/s reported $5.95B in cash and cash equivalents in its most recent financial results.

What is Novo Nordisk A/s’s dividend yield?

Novo Nordisk A/s does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services